Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems. Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE). Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical. In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG 35-55 )-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-a, IL-6, IFN-c (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFb, and IL-4 (Th2)) in the CNS and lymph nodes. Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4 + CD25 +
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+ Tregs were strikingly reduced in VPAC2-deficient mice with EAE. Finally, the in vitro suppressive activity of lymph node and splenic Tregs from VPAC2-deficient mice was impaired. Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool. Ó 2014 Elsevier Inc. All rights reserved.
Introduction
Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP), are two secretin family neuropeptides widely expressed in the central, autonomic, sensory, and enteric nervous systems, acting through the G proteincoupled receptors VPAC1, VPAC2 and PAC1 (Vaudry et al., 2009 ). Whereas PACAP binds with similar high affinity to all three of these receptors, VIP binds only VPAC1 and VPAC2. Each of these receptors is strongly coupled through G as protein to adenylyl cyclase, leading to cAMP production and subsequent activation of protein kinase A (PKA) and in some cases, EPACs (exchange protein directly activated by cAMP, also known as cAMP-GEF). However, a few other parallel signaling pathways have been described. For example, they also couple with G ai and G aq proteins that regulate signaling molecules as diverse as PKC, PLC, PLD and src, and elevate the intracellular secondary messengers IP 3 , DAG and Ca 2+ (Vaudry et al., 2009 ). Activation of different signaling pathways seems to be dependent on the cellular type/activation status and in the case of PAC1, of the receptor splice variant expressed. The expression and actions of VIP, PACAP and their receptors in preganglionic and postganglionic neurons of the sympathetic nervous system (SNS) (Beaudet et al., 1998; Pettersson et al., 2004; Tanida et al., 2010; May and Braas, 1995; Gray et al., 2002; Braas et al., 2007; Girard et al., 2004) suggest that they may function in the autonomic regulation of stress responses, including those associated with inflammation (Nance and Sanders, 2007; Bellinger et al., 2008) . In this regard, VIP-immunoreactive fibers, presumably arising from sympathetic neurons, have been demonstrated in lymph nodes, spleen and thymus of rats (Bellinger et al., 1997) , and nearly all immune cell types express one or more receptor subtypes http://dx.doi.org/10.1016/j.bbi.2014.09.020 0889-1591/Ó 2014 Elsevier Inc. All rights reserved.
